BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved BREAKING FDA UPDATE MASSIVE FOR PEPTIDES The U.S. Food & Drug Administration is reportedly reclassifying 14 peptides from Category 2 (compounding only, no legal prescribing) into Category 1. This means FDA considers adding a dozen peptides to its bulk drug compounding list RAPS BREAKING NEWS: HHS Secretary Kennedy just announced that the FDA is taking a step toward restoring science based access by removing 12 peptides from Category 2 and advancing them for formal review.